Immunization with HIV protease peptides linked to syngeneic erythrocytes

被引：7

作者：

Boberg A. ^{[1
,2
]}

Dominici S. ^{[3
]}

Brave A. ^{[1
,2
]}

Hallermalm K. ^{[1
,2
]}

Hinkula J. ^{[4
]}

Magnani M. ^{[3
]}

Wahren B. ^{[1
,2
]}

机构：

[1] Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm

[2] Swedish Institute for Infectious Disease Control, Stockholm

[3] Institute of Biochemistry G. Fomaini, University of Urbino, Urbino

[4] Department for Molecular Virology, Faculty of Health Science, Linköping University, Linköping

来源：

Infectious Agents and Cancer | / 2卷 / 1期

关键词：

Peptide; Delivery Vector; Strong Immune Response; Vaccine Adjuvant; Soluble Peptide;

D O I：

10.1186/1750-9378-2-9

中图分类号：

学科分类号：

摘要：

New potent vaccine adjuvants are desirable for increasing the efficacy of novel vaccine modalities such as DNA and peptides. We therefore tested if syngeneic erythrocytes could serve as delivery vectors for selected HIV peptides and compared the potency of these constructs to immunization with peptides in phosphate buffered saline or in incomplete Freunds adjuvant Immunization of mice with peptides in a low dose (5 ng) coupled to erythrocytes induced a weak immune response in mice. These peptides alone (5 μg) gave no immune responses, while formulating the peptides (50 μg) in IFA induced strong homologous immunity as well as prominent cross reactivity to a related mutant epitope. Thus, vaccine delivery using syngeneic erythrocytes, although attractive for clinical use, might be of limited value due to the low amount of antigen that can be loaded per erythrocyte.

引用

共 13 条

[1]

Asjo B., Stavang H., Sorensen B., Baksaas I., Nyhus J., Langeland N., Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy, AIDS Res Hum Retroviruses, 18, pp. 1357-1365, (2002)

[2]

Pialoux G., Gahery-Segard H., Sermet S., Poncelet H., Fournier S., Gerard L., Tartar A., Gras-Masse H., Levy J.P., Guillet J.G., Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers, Aids, 15, pp. 1239-1249, (2001)

[3]

Sommerfell M.A., Nyhus J., Sorensen B., Novel peptide-based HIV-1 immunotherapy, Expert Opin Biol Ther, 4, pp. 349-361, (2004)

[4]

Karlsson A.C., Deeks S.G., Barbour J.D., Heiken B.D., Younger S.R., Hoh R., Lane M., Sallberg M., Ortiz G.M., Demarest J.F., Et al., Dual Pressure from Antiretroviral Therapy and Cell-Mediated Immune Response on the Human Immunodeficiency Virus Type 1 Protease Gene, J Virol, 77, pp. 6743-6752, (2003)

[5]

Chiarantini L., Vaccination Strategy Using Red Blood Cells as Antigen Delivery System, (2003)

[6]

Dominici S., Laguardia M.E., Serafini G., Chiarantini L., Fortini C., Tripiciano A., Brocca-Cofano E., Scoglio A., Caputo A., Fiorelli V., Et al., Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL, Vaccine, 21, pp. 2073-2081, (2003)

[7]

Chiarantini L., Argnani R., Zucchini S., Stevanato L., Zabardi P., Grossi M.P., Magnani M., Manservigi R., Red blood cells as delivery system for recombinant HSV-1 glycoprotein B: Immunogenicity and protection in mice, Vaccine, 15, pp. 276-280, (1997)

[8]

Chiarantini L., Matteucci D., Pistello M., Mancini U., Mazzetti P., Massi C., Giannecchini S., Lonetti I., Magnani M., Bendinelli M., AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: Homologous erythrocytes as a delivery system for preferential immunization with putative protective antigens, Clin Diagn Lab Immunol, 5, pp. 235-241, (1998)

[9]

Magnani M., Chiarantini L., Mancini U., Preparation and characterization of biotinylated red blood cells, Biotechnol Appl Biochem, 20, PART 3, pp. 335-345, (1994)

[10]

Chiarantini L., Droleskey R., Magnani M., DeLoach J.R., In vitro targeting of erythrocytes to cytotoxic T-cells by coupling of Thy-1.2 monoclonal antibody, Biotechnol Appl Biochem, 15, pp. 171-184, (1992)

← 1 2 →